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Background: Recent substance abuse research indicates gender differences in the substance-related epidemiology,
biological responses, progression to dependence, medical consequences and treatments. Studies exploring human
sex-different responses to ketamine are rare and there has been no systemic survey of gender differences in
ketamine use. Determining whether females are more susceptible than males to ketamine withdrawal symptoms
and adverse effects is important, because it associated with treatment retention and outcome in drug users.
Methods: The Taiwanese juridical system has implemented a new regulation on ketamine in the year 2009.
Ketamine users who are caught by the police, are mandated to attend an educational program. We recruited
ketamine offenders from February 2010 to May 2012 at the Kunming branch of the Taipei City Hospital, where the
educational classes are held. A designed questionnaire was performed to gather information about demographic
characteristics, discontinuation symptoms, concomitant use of other substances, and subjective experience of
memory impairment or urinary discomforts, and to compare the gender differences.
Results: A total of 1,614 ketamine users were surveyed and most of them were males (83.8%), with an average age
of 26.3 ± 5.4 years. Female ketamine users presented significantly more discontinuation symptoms such as anxiety,
dysphoria, and tremors compared with male users. 72.4% of total ketamine users smoked cigarettes concomitantly.
Male ketamine users had a higher rate of concomitant betel nut use, while female ketamine users had a higher rate
of concomitant hypnotic and alcohol use. 76% of total ketamine users reported cognitive impairment and 51.6%
mentioned urinary symptoms. Furthermore, female ketamine users self-reported significantly greater levels of
severity in cognitive impairment and urinary discomforts compared with male users. Less than 10% of total
ketamine users in our study reported the desire to transfer for medical intervention or treatment, despite the high
rates of discontinuation symptoms and negative physical side effects.
Conclusions: Gender differences were noted in the subjective experience of discontinuation symptoms,
concomitant substance use, and severity of impairment related to ketamine use. However, the probable cause of
the gender differences found in this study requires further investigation. We hoped our study will stimulate further
research in this field.
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Ketamine is an anesthetic derivative of phencyclidine
(PCP) with dissociative, analgesic and psychedelic prop-
erties. Although ketamine is classified as a hallucinogen,
it is widely used in a variety of anesthetic procedures in
pediatric, obstetric and geriatric patients [1]. Moreover,
the antidepressant effects of ketamine in treating refrac-
tory depression were reported in recent years [2].
According to the latest systemic review by Morgan
and Curran [3], there are now increasing concerns
about the harmful physical and psychological conse-
quences of repeated misuse of ketamine. Acute physical
harms include risk of death from accidents, acute car-
diac risk from poisoning; ketamine-induced chronic
physical harms include ulcerative cystitis, renal dysfunc-
tion and ‘k-cramps’. Frequent, daily use is also associated
with neurocognitive impairment, and most robustly, de-
ficits in working and episodic memory [4]. Psychological
effects of chronic ketamine use were related to depression
and psychosis [5]. Ketamine withdrawal symptoms charac-
terized by anxiety, shaking, sweating, palpitations and
carvings seem to be key problems in frequent ketamine
users and have been published by many case studies [6-8].
However, there has yet to be a coherent and agreed upon
description of a specific ketamine withdrawal syndrome to
guide treatment and diagnosis. A rapid development of
tolerance was demonstrated in ketamine users, and many
frequent users are concerned about addiction and report
trying but failing to stop using ketamine. Ketamine de-
pendence can lead to costly health services, which include
the treatment of the addiction and its related impairments
in social functions, as well as the chronic physical health
problems that will likely incur follow-up costs across
the lifespan.
Recreational use of ketamine was first documented on
the west coast of the United States in the early 1970s [9].
Ketamine has not been a major drug of abuse within the
past two decades, and only a few cases have been reported
during this time [10,11]. After the ecstasy epidemic, keta-
mine use has become more popular in recent years around
the world, especially as a common club drug among the
dance, rave, and squat party scenes. It is also becoming
popular in the United Kingdom [12,13], Australia [14],
Hong Kong [15,16], and Mainland China [17]. In the latest
World Drug Report by United Nations Office on Drugs
Control (UNODC) 2013 [18], Ketamine belong to new psy-
choactive substance (NPS) and not controlled by inter-
national drug conventions, but which may pose a public
health threat. Part of ketamine’s growing popularity in
South-East Asia may be due to its lower status in the regu-
latory systems and lower price point as a substitute for the
increasingly expensive ‘ecstasy’ or methamphetamine.
Ketamine has also become a commonly abused sub-
stance in Taiwan during recent years, especially amongyouths and adolescents [19-21]. Evidence showed that most
ketamine users in Taiwan also used ecstasy (MDMA) con-
comitantly. Detected rates of MDMA and ketamine were
found to be as high as 76% and 47% respectively among
rave party participants in Taiwan [20]. Leung et al. [22] con-
ducted a focus group with club drug users and noted that
there was a special drug use sequence widely practiced by
Taiwanese poly-drug users. In a single drug use episode,
MDMA was usually the first drug used, followed by keta-
mine and then marijuana. This unique sequence of poly-
drug use in a single episode is called “Trinity”.
Ketamine is scheduled as level III in the “Narcotic
Harm Control Act” in Taiwan. Pure ketamine use is
regarded as an offense and not a crime. One reason for
the increase in the abuse of ketamine in recent years is
the lack of restriction by authorities. Reports from the
Ministry of Justice showed increase in both the amount
of street ketamine seized by the police, as well as the
number of offenders (namely drug dealers or traffickers).
Around 3000 to 4000 offenders were caught by the po-
lice in Taiwan per month during the year 2012.
Recent substance abuse research indicates gender differ-
ences in the substance-related epidemiology, social factors,
biological responses, progression to dependence, medical
consequences, co-occurring psychiatric disorders, and bar-
riers to treatment entry, retention, and completion [23].
For examples, in alcohol drinking, women’s drinking-
related problems appear to progress more quickly than
those of men [24], and women report more severe prob-
lems and experience more health-related consequences
from substance use [25]. Stimulants may enhance sex dif-
ferences in the dopamine system in limbic regions, which
may partly mediate sex difference in drug abuse [26].
Craving and relapse of drug seeking in abstinent individ-
uals have also been found to differ between men and
women, and there is robust evidence that women are
more likely to initiate drug misuse and relapse into drug
use after withdrawal than men [27]. In ecstasy use, gender
was found to significantly moderate the relationship be-
tween the consumption and design fluency [28]. When
addicted to cocaine or amphetamine, women showed
more impairment in decision making than men [29]. Stud-
ies exploring human sex-different responses to ketamine
are rare. An animal study by Winters et al, who compared
the differing analgesic effects of ketamine in male and fe-
male rats, indicated that females were much more sensi-
tive to ketamine than males [30,31]. Moreover, female rats
showed a greater sensitivity to ketamine neurotoxicity and
brain neural loss compared to males [32]. Determining
whether females are more susceptible than males to keta-
mine withdrawal symptoms and adverse effects is import-
ant, especially in cognitive deficits, because it associated
with treatment retention and outcome in drug users [33].
The aim of this study is to further the management
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Taiwan. The researchers collected information on relevant
demographic and clinical data, so as to analyze the pattern
of ketamine use, the discontinuation symptoms, the pro-
gression of harm, users’ willingness to seek treatment, and




In light of the increasingly severe problem of ketamine
abuse, the Taiwanese juridical system implemented a new
regulation that focused on ketamine users beginning in
2009. This new regulation stipulates that offenders caught
by the police for using ketamine (as evidenced by urine
screen results) will receive a fine ranging from 10,000 to
50,000 NT dollars and attend a mandatory educational
class for 4-8 hours. The mandatory class presents an op-
portunity for the investigator to come into contact with
ketamine users within a larger sample.
We recruited ketamine offenders from February 2010
to May 2012 at the Kunming branch of the Taipei City
Hospital where the educational classes are held. Since we
were not aware of established questionnaires to examine
ketamine-related problems, we designed a questionnaire
to include demographic characteristics, age, reasons for
initial use of ketamine, likes and dislikes during ketamine
use, experience of discontinuation symptoms related to
ketamine, and current concomitant substance use. The
survey contained additional questions regarding the de-
gree of memory impairment and urinary discomforts. In-
formation about reasons for ketamine use and users’ likes
and dislikes during ketamine use was collected by open
questions, while the remainder of the information was
gathered through checklist questions. Since the Chinese
version of the pelvic pain and urgency/frequency (PUF)
questionnaire has been shown to be reliable and valid for
assessment in patients with lower urinary tract symptoms
associated with street-ketamine use [34], and the cut-off
value of the total score range from 13-17 with detecting
interstitial cystitis among different literature reviews
[34,35]. We divided items assessing for urinary discom-
forts into three groups: Nil, Mild, and Severe, to separate
the servility among the ketamine users who may beyond
the cut-off points. Nil indicates never experiences of the
pelvic pain or urgency/frequency; Mild indicates symp-
toms such as urgency/frequency occasionally but not usu-
ally; Severe indicates symptoms such as both pelvic pain
and urgency/frequency, or one of the symptoms achieve
usually or always, or having received clinical helps. The se-
vere group could indicate the total score above 11 in the
PUF questionnaire. However, there was no known vali-
dated self-report scale to evaluate ketamine-related mem-
ory impairments. Therefore, we designed a self-reportquestionnaire that categorizes memory impairment into
three levels of severity: Nil, Mild, and Severe. Nil indicates
no memory impairments; Mild indicates slight memory
impairments; Severe indicates obvious signs of memory
decline.
During the educational class, the research assistant pro-
vided a comprehensive description of the questionnaire,
and all subjects were informed that their legal status
would not be influenced by whether or not they partici-
pated in the study. The procedure was confidential. Partic-
ipants were not required to identify themselves unless
they wished to leave their personal information for referral
to further medical evaluation or intervention. The Institu-
tional Review Board of Taipei City Hospital, which has
been certificated by Forum for Ethical Review Committees
in Asian and Western Pacific Region (FERCAP) has ap-
proved this study (TCHIRB-971212).
Data analysis
Demographic and clinical characteristics of the patients
were analyzed by Student t-test or Chi-square test. Stat-
istical analyses were performed using SPSS version 12.0.
Results were considered statistically significant at p < .05.
age-adjusted associations between genders and risk of
Logistic regression analysis was also conducted to assess
ketamine-related cognitive impairment or urinary symptoms.
Results
Demographics
Of the 1624 ketamine offenders, 10 either refused or
failed to complete the questionnaire. Therefore, our ana-
lysis included data from 1614 participants (Mean age:
26.3 ± 5.4 years; Male to female ratio: 5:1). Demographic
characteristics are displayed in Table 1, with gender
comparison. Most of them were males (83.3%), single
(88.0%) and employed (83.9%). The average duration of
ketamine use was about 4 years.
Concomitant substance use and discontinuation
symptoms
Among the ketamine offenders, 72.4% smoked cigarettes
and 16.5% consumed alcohol. It was found that more
male than female users used betel nut concomitantly.
Also, female users used more hypnotics and alcohol than
males. The prevalence of other concomitant substance
use among ketamine users is also displayed in Table 1.
When stopping ketamine use, the most common dis-
comfort mentioned by participants was fatigue (26.0%),
followed by poor appetite (20.4%) and drowsiness (19.1%).
Cravings, as well as anxiety and dysphoria, were common
psychological symptoms at the discontinuation of ketamine
use, especially in females. In addition, 3-5% of participants
experienced physical symptoms such as palpitation, sweat-
ing or tremors during discontinuation. Gender differences
Table 1 Demographics information and clinical data in ketamine users
Total Male Female P value
Age, years ± SD (range) 26.3 ± 5.4 (15-54) 26.5 ± 5.5 (15-54) 25.0 ± 4.3 (18-38) <0.001***
Gender, n (%) 1614 1353 (83.8%) 261(16.2%) <0.001***
Marriage status (%) Single 88.0 88.1 87.5 0.013*
Married 11.2 11.1 12.1
Others 0.8 0.8 0.4
Education, years ± SD 12.1 ± 2.3 12.2 ± 2.4 11.8 ± 2.1 0.056
Occupation On job, n (%) 1354 (83.9) 1143 (84.5) 211(80.7)
Jobless, n (%) 252 (15.6) 202 (14.9) 50 (19.1)
Age of first ketamine use, years ± SD 22.1 ± 5.7 22.3 ± 5.8 21.2 ± 4.8 0.001**
Other substance use (%) Cigarette 72.4 73.9 64.8 0.002**
Alcohol 16.5 15.7 20.7 0.049*
Betel nut 15.8 18.4 2.3 <0.001***
Hypnotics 4.7 2.7 15.3 <0.001***
MDMA 4.4 4.1 5.7 0.246
Meth-amphetamine 1.6 1.4 2.7 0.133
Marijuana 1.5 1.6 1.1 0.622
Heroin 0.5 0.5 0.4 0.777
Glue 0.4 0.5 0.0 0.244
P value: difference between genders.
*p < 0.05, **p< 0.01, ***p< 0.001.
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ketamine users presented with significantly more anxiety
(23.4%), dysphoria (24.1%) and tremors (6.5%) compared
with male users during ketamine discontinuation.
Self-report about the cognitive impairment, urinary
discomfort, and motivation to seek medical intervention
22.4% of total ketamine offenders reported that their
cognitive ability was severely impaired by ketamine use,
particularly in females (27.5%). In addition, more than
half of the total participants had urinary symptoms.Table 2 Subjective reports of symptoms during ketamine disc










Great effort to resist use 4.0
P value: difference between genders.
*p < 0.05, **p< 0.01.Compared with males, female ketamine offenders were
more likely to develop severe cognitive impairment (OR,
95% CI =1.717, 1.075-2.741) and urinary symptoms
(2.719, 1.501-4.928) according to their self-report. Gen-
der differences in subjective reports of cognitive impair-
ment and urinary tract symptoms among ketamine users
are shown in Table 3.
Despite 76% of ketamine users reporting cognitive im-
pairment and 51.6% mentioning urinary symptoms, only
7% of ketamine users in our study opted to seek medical
intervention or treatment under our transfer, with alsoontinuation











Table 3 Subjective cognitive impairment and urinary tract symptoms among ketamine users and the adjusted odds
ratios (AORs) between genders
Total Male Female AORsc P value 95% CI
Cognitive impairment Nil 23.9% 24.7% 20.2% reference - -
mild 53.6% 53.9% 52.3% 1.275 0.258 0.837-1.942
severe 22.4% 21.4% 27.5% 1.717 0.024* 1.075-2.741
Urinary tract symptoms Nil 49.5% 49.7% 48.4% reference - -
milda 45.8% 46.5% 41.9% 0.915 0.601 0.656-1.276
severeb 4.8% 3.8% 9.7% 2.719 0.001** 1.501-4.928
aIndicating symptoms as urgency/frequency occasionally but not usually.
bIndicating symptoms as both pelvic pain and urgency/frequency, or one of the symptoms achieved usually or always, or having received clinical help.
cThe reference category is Nil group in cognitive impairment and urinary tract symptoms respectively, after adjusted age.
P value: the risk of subjective cognitive impairment or urinary tract symptoms between genders 95% CI, 95% confidence intervals.
*p < 0.05, ** p< 0.01.
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female:11.7%; p = .001).
Discussion
In this study, we explored the discontinuation symptoms
of ketamine offenders in Taiwan, and examined the gender
difference. The results demonstrated that female ketamine
users had more severe self-report cognitive impairment
and urinary symptoms related to ketamine use than male
users. Our study is the first with a large sample size that
showed a gender difference in the complications of keta-
mine use. The possible implication of our findings will be
discussed.
Discontinuation symptoms
Pharmacologically, ketamine’s main action is on glutamate,
the major excitatory neurotransmitter in the brain. It is a
non-competitive antagonist at one of the three glutamate
receptors: the N-methyl d-aspartate (NMDA) receptor [3].
Ketamine also has less prominent actions at other receptor
sites. It blocks muscarinic acetylcholine receptors and may
potentiate the effects of gamma-aminobutyric acid (GABA)
synaptic inhibition. In addition, ketamine induces activation
of dopamine release [36] and acts as a weak agonist at μ
opioid receptors [37]. Ketamine’s affinity to multiple recep-
tors could theoretically explain its effects on cognition,
mood, psychotic experiences and withdrawal symptoms.
Even though most of the participants in this study are poly-
drug users and the discontinuation symptoms reported
here may have been the result of a combination of different
substances, ketamine users related their symptoms to the
discontinuation of ketamine in the questionnaire.
It is unclear if physical symptoms occur during keta-
mine withdrawal. However, the discontinuation symp-
toms mentioned in our questionnaire are quite similar
to alcohol withdrawal. In fact, alcohol consumption was
found to reduce certain ketamine discontinuation symp-
toms, such as anxiety, shaking, sweating, palpitation, and
low mood [6]. Ketamine discontinuation can result inglutamate rebound with symptoms reminiscent of NMDA
over-activity in alcohol withdrawal [6]. It is plausible that
modified forms of alcohol withdrawal regimens can lessen
symptoms of ketamine discontinuation.
Gender difference
Gender differences were found in the participants’ sub-
jective reports of discontinuation symptoms, as well as
concomitant substance use and severity of impairment
related to ketamine. In addition, female ketamine users
reported a higher proportion of alcohol or hypnotic con-
sumption compared to males. This tendency may be re-
lated to the significantly higher amounts of self-reported
discontinuation symptoms such as anxiety and tremors
in female ketamine users. In an animal study, it was sug-
gested that the gonadal hormones in female rats played
a critical role in enhancing the antidepressant-like effects
of ketamine [38]. Therefore, we surmised that female
ketamine users tended to experience dysphoric mood
more frequently than males during ketamine discontinu-
ation, as shown in our study.
A study about gender differences in abusers of
amphetamine-type stimulants (ATS) and ketamine (K) in
southwestern China [39] compared gender trends in ATS
and ATS +K patients. For males, the ATS + K patients
were more likely to develop psychotic disorders than ATS
patients. For females, the ATS + K patients were more
likely to develop cognitive impairment than ATS patients.
Due to the central role of the NMDA-receptor in learning
and memory, both acute and chronic use of ketamine ex-
erts specific and wide-ranging effects on memory systems
[4]. In line with previous animal study, female ketamine
users were more vulnerable to cognitive deficits compared
with males. On the other hand, a UK study showed an ab-
sence of gender difference in urinary symptoms among
recreational ketamine users [40]. However, female keta-
mine offenders were more likely to develop severe urinary
discomforts in our findings. This suggests that female
ketamine users may experience a greater amount of
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them to seek medical intervention.
Biological mechanisms underlying female-specific keta-
mine effects are largely unknown. Acute administration of
ketamine has been reported to decrease serum sex hor-
mones including estradiol, progesterone, and testosterone
in female rats [41]. It is possible that repeated ketamine
may have specific effects on women via sex hormones;
however, the probable cause of the gender differences
found in this study requires further investigation.
Limitation
Our results should be interpreted with some limitations in
mind. First, since participants were recruited while being
mandated by the law to attend the class, it was difficult to
validate the actual frequency and amount of ketamine and
concomitant substance use, and thus the data related to
substance use should be underestimated. We designed the
confidential self-report to have favorable ascertainment.
Second, in the absence of established questionnaires to
examine ketamine-related problems (e.g., discontinuation
symptoms), the questionnaires we used have not been
studied to determine reliability and validity. There was no
definition of cognitive impairment in the questionnaire, so
the severity may be inconsistent between individual. Third,
the discontinuation symptoms reported in our study may
have been the result of a combination of different sub-
stances; however, ketamine users related their symptoms
to the discontinuation of ketamine in the questionnaire.
Researchers should be cautious to generalize our results
given the high comorbidity of substance use disorder with
other mental health issues. In this study, neuropsychiatric
disorders or current affective state were not identified.
Previous studies showed that the lifetime rates of mood
and anxiety disorders are significantly higher among
women than men, with and without substance-use disor-
ders [42]. Associations between most substance use disor-
ders and independent mood and anxiety disorders were
positive and significant [43]. It is important to conduct a
more comprehensive psychiatric assessment to determine
whether substance use may enhance vulnerability for these
disorders, or lead to organic changes that manifest as a
mood or anxiety disorder. Finally, there might be gender
differences on how participants responded to the self-
report questionnaires. Gender was an important demo-
graphic factor associated with symptom reporting, and
most physical symptoms are typically reported more often
by women than by men [44]. We cannot exclude the
potential effects of gender on self-reporting biases in
this study.
Implications
Ketamine has had a turbulent history since its first use
as a clinical anesthesia for humans in 1964 [45]. With itsanalgesic-anesthetic mechanisms and antidepressant ef-
fect, ketamine is associated with a high potential for
abuse or dependence. The pros and cons of ketamine
use, as well as other areas of uncertainty regarding its
use (e.g. antidepressant effect), deserve further studies in
the future.
Despite several limitations generalizing data derived
from our study, experience has shown us that investigating
subjects with substance use can be extremely difficult. This
is the first article demonstrating the correlation between
gender and ketamine-related problems. Our study demon-
strated that female ketamine users had more severe self-
reported cognitive impairment and urinary symptoms than
male users. These findings were compatible with previous
animal study. However, a lot of additional work is required
for a better understanding of gender differences in ke-
tamine use. We hoped our study will stimulate further
research in this field. Currently, there are no guidelines for
effective management of ketamine withdrawal effects or
dependence [46]. As ketamine abuse and dependence
grows, addiction services need to be better informed of the
effects of this drug, especially among young females. Pol-
icies emphasizing the increased vulnerability to ketamine-
related adverse effects in female users compared with male
users and offering the opportunity to enhance medical ac-
cessibility may improve efforts to prevent progression of
ketamine dependence. Further studies should aim to ad-
dress the health problems experienced by this group and
explore the best approach to treat ketamine addiction.
Conclusions
Discontinuation symptoms and physical side-effects are
not uncommon in these ketamine offenders. Gender dif-
ferences were noted in the subjective experience of dis-
continuation symptoms, concomitant substance use, and
severity of impairment related to ketamine use. Additional
work is required for a better understanding of the gender
differences found in this study. Ketamine users in Taiwan
are generally relatively young; therefore, further studies
should be conducted to increase the availability and acces-
sibility of effective treatment interventions, and preventa-
tive public education.
Abbreviations
PCP: Phencyclidine; UNODC: United Nations Office on Drugs Control; NPS: New
psychoactive substance; MDMA: 3,4-methylenedioxy-N-methylamphetamine;
NMDA: N-methyl d-aspartate; GABA: Gamma-aminobutyric acid.
Competing interests
The authors declare that there is no conflict of interest of this study.
Authors’ contributions
YWC and SKL designed the protocol and carried the survey. They gathered
and analyzed the study’s data, and wrote the first draft of the manuscript.
MCH assisted with the study’s design and in the preparation of this
manuscript. All authors read and approved the final manuscript.
Chen et al. Substance Abuse Treatment, Prevention, and Policy 2014, 9:39 Page 7 of 7
http://www.substanceabusepolicy.com/content/9/1/39Acknowledgements
This study was supported by Taipei City Government (99001-62-050) and
granted from National Science Council, Taiwan (NSC 101-2314-B-532 -002 -MY2).
The authors wish to express their deepest gratitude to all participants of this
study.
Received: 27 December 2013 Accepted: 8 July 2014
Published: 22 September 2014References
1. White PFWW, Trevor AJ: Ketamine–its pharmacology and therapeutic
uses. Anesthesiology 1982, 56:119–136.
2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS,
Krystal JH: Antidepressant effects of ketamine in depressed patients.
Biol Psychiatry 2000, 47(4):351–354.
3. Morgan CJ, Curran HV: Ketamine use: a review. Addiction 2011,
107(1):27–38.
4. Morgan CJ, Curran HV: Acute and chronic effects of ketamine upon
human memory: a review. Psychopharmacology (Berl) 2006, 188(4):408–424.
5. Morgan CJ, Muetzelfeldt L, Curran HV: Consequences of chronic ketamine
self-administration upon neurocognitive function and psychological
wellbeing: a 1-year longitudinal study. Addiction 2010, 105(1):121–133.
6. Critchlow DG: A case of ketamine dependence with discontinuation
symptoms. Addiction 2006, 101(8):1212–1213.
7. Lim DK: Ketamine associated psychedelic effects and dependence.
Singapore Med J 2003, 44(1):31–34.
8. Blachut M, Solowiow K, Janus A, Ruman J, Cekus A, Matysiakiewicz J, Hese
RT: [A case of ketamine dependence]. Psychiatr Pol 2009, 43(5):593–599.
9. Petersen RC SR, Stillman RC: Phencyclidine: an overview. NIDA Res Monogr
1978, 21:1–17.
10. Hurt PH, Ritchie EC: A case of ketamine dependence. Am J Psychiatry 1994,
151(5):779.
11. Jansen KL, rracotCankovic R: The nonmedical use of ketamine, part two: A
review of problem use and dependence. J Psychoactive Drugs 2001,
33(2):151–158.
12. Morgan CJ, Monaghan L, Curran HV: Beyond the K-hole: a 3-year longitudinal
investigation of the cognitive and subjective effects of ketamine in
recreational users who have substantially reduced their use of the drug.
Addiction 2004, 99(11):1450–1461.
13. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV: Journey
through the K-hole: phenomenological aspects of ketamine use.
Drug Alcohol Depend 2008, 95(3):219–229.
14. Dillon P, Copeland J, Jansen K: Patterns of use and harms associated with
non-medical ketamine use. Drug Alcohol Depend 2003, 69(1):23–28.
15. Cheng WC, Ng KM, Chan KK, Mok VK, Cheung BK: Roadside detection of
impairment under the influence of ketamine–evaluation of ketamine
impairment symptoms with reference to its concentration in oral fluid
and urine. Forensic Sci Int 2007, 170(1):51–58.
16. Ng SH, Tse ML, Ng HW, Lau FL: Emergency department presentation of
ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J
2010, 16(1):6–11.
17. Fang YX, Wang YB, Shi J, Liu ZM, Lu L: Recent trends in drug abuse in
China. ActaPharmacol Sin 2006, 27(2):140–144.
18. The United Nations Office on Drugs and Crime (UNODC): World Drug
Report. United Nations publication(Sales No. E.13.XI.6); 2013.
19. Chen WJ, Fu TC, Ting TT, Huang WL, Tang GM, Hsiao CK, Chen CY: Use of
ecstasy and other psychoactive substances among school-attending
adolescents in Taiwan: national surveys 2004-2006. BMC Public Health
2009, 9:27.
20. Lua AC, Lin HR, Tseng YT, Hu AR, Yeh PC: Profiles of urine samples from
participants at rave party in Taiwan: prevalence of ketamine and MDMA
abuse. Forensic Sci Int 2003, 136(1-3):47–51.
21. Yen CF, Hsu SY, Cheng CP: Polysubstance use and its correlates in
adolescent ecstasy users in Taiwan. Addict Behav 2007, 32(10):2286–2291.
22. Leung KS, Li JH, Tsay WI, Callahan C, Liu SF, Hsu J, Hoffer L, Cottler LB:
Dinosaur girls, candy girls, and Trinity: voices of Taiwanese club drug
users. J Ethn Subst Abuse 2008, 7(3):237–257.
23. Tuchman E: Women and addiction: the importance of gender issues in
substance abuse research. J Addict Dis 2010, 29(2):127–138.24. Randall CL, Roberts JS, Del Boca FK, Carroll KM, Connors GJ, Mattson ME:
Telescoping of landmark events associated with drinking: a gender
comparison. J Stud Alcohol 1999, 60(2):252–260.
25. Bradley KA, Badrinath S, Bush K, Boyd-Wickizer J, Anawalt B: Medical risks
for women who drink alcohol. J Gen Intern Med 1998, 13(9):627–639.
26. Anker JJ, Carroll ME: Females are more vulnerable to drug abuse than
males: evidence from preclinical studies and the role of ovarian
hormones. Curr Top Behav Neurosci 2011, 8:73–96.
27. Fattore L, Fadda P, Fratta W: Sex differences in the self-administration of
cannabinoids and other drugs of abuse. Psychoneuroendocrinology 2009,
34(Suppl 1):S227–S236.
28. Medina KL, Shear PK, Corcoran K: Ecstasy (MDMA) exposure and
neuropsychological functioning: a polydrug perspective.
J Int Neuropsychol Soc 2005, 11(6):753–765.
29. van der Plas EA, Crone EA, van den Wildenberg WP, Tranel D, Bechara A:
Executive control deficits in substance-dependent individuals: a comparison
of alcohol, cocaine, and methamphetamine and of men and women.
J Clin Exp Neuropsychol 2009, 31(6):706–719.
30. Winters WD, Hance AJ, Cadd GC, Lakin ML: Seasonal and sex influences on
ketamine-induced analgesia and catalepsy in the rat; a possible role for
melatonin. Neuropharmacology 1986, 25(10):1095–1101.
31. Lees J, Hallak JE, Deakin JF, Dursun SM: Gender differences and the effects
of ketamine in healthy volunteers. J Psychopharmacol 2004, 18(3):337–339.
32. Jevtovic-Todorovic V, Wozniak DF, Benshoff ND, Olney JW: A comparative
evaluation of the neurotoxic properties of ketamine and nitrous oxide.
Brain Res 2001, 895(1-2):264–267.
33. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM: Cognitive enhancement as a
treatment for drug addictions. Neuropharmacology 2013, 64:452–463.
34. Ng CM, Ma WK, To KC, Yiu MK: The Chinese version of the pelvic pain and
urgency/frequency symptom scale: a useful assessment tool for
street-ketamine abusers with lower urinary tract symptoms. Hong Kong
Med J 2012, 18(2):123–130.
35. Kushner L, Moldwin RM: Efficiency of questionnaires used to screen for
interstitial cystitis. J Urol 2006, 176(2):587–592.
36. Rabiner EA: Imaging of striatal dopamine release elicited with NMDA
antagonists: is there anything there to be seen? J Psychopharmacol 2007,
21(3):253–258.
37. Oye I, Paulsen O, Maurset A: Effects of ketamine on sensory perception:
evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp
Ther 1992, 260(3):1209–1213.
38. Carrier N, Kabbaj M: Sex differences in the antidepressant-like effects of
ketamine. Neuropharmacology 2013, 70:27–34.
39. Zhang Y, Lu C, Zhang J, Hu L, Song H, Li J, Kang L: Gender differences in
abusers of amphetamine-type stimulants and ketamine in southwestern
China. Addict Behav 2013, 38(1):1424–1430.
40. Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM: The prevalence and
natural history of urinary symptoms among recreational ketamine users.
BJU Int 2012, 110(11):1762–1766.
41. Lee CJ, Do BR, Kim JK, Yoon YD: Pentobarbital and ketamine suppress
serum concentrations of sex hormones in the female rat. J Anesth 2000,
14(4):187–190.
42. Greenfield SF, Back SE, Lawson K, Brady KT: Substance abuse in women.
Psychiatr Clin North Am 2010, 33(2):339–355.
43. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W,
Pickering RP, Kaplan K: Prevalence and co-occurrence of substance use
disorders and independentmood and anxiety disorders: Results from the
national epidemiologic survey on alcohol and relatedconditions.
Arch Gen Psychiatry 2004, 61(8):807–816.
44. Kroenke K, Spitzer RL: Gender differences in the reporting of physical and
somatoform symptoms. Psychosom Med 1998, 60(2):150–155.
45. Domino EF: Taming the ketamine tiger. 1965. Anesthesiology 2010,
113(3):678–684.
46. Garg A, Sinha P, Kumar P, Prakash O: Use of naltrexone in ketamine
dependence. Addict Behav 2014, 39(8):1215–1216.
doi:10.1186/1747-597X-9-39
Cite this article as: Chen et al.: Gender differences in subjective
discontinuation symptoms associated with ketamine use. Substance
Abuse Treatment, Prevention, and Policy 2014 9:39.
